Non-alcoholic steatohepatitis. nonalcoholic steatohepatitis
Conditions
Interventions
Intervention 1: Intervention group:
Patients will receive 250 mg cinnamon capsules, prepared in Shiraz University of Medical Sciences, faculty of pharmacy, 4 times a day for two months. Related tests
Treatment - Drugs
Intervention group:
Patients will receive 250 mg cinnamon capsules, prepared in Shiraz University of Medical Sciences, faculty of pharmacy, 4 times a day for two months. Related tests will be done a
Control group:
Patients will receive 400 mg Osve Vitamin E capsule, once daily for two months. Related tests will be done at the beginning of the study and the end of every four weeks. To get more c
Sponsors
Vice –Chancellor of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of the study: ALT level higher than 65U/L; Diagnosed fatty liver in ultrasonography; No alcohol and drug abuse; No history of chemotherapy in the past years; No history of other chronic liver diseases such as hepatitis B and hepatitis C, cirrhosis, bile diseases, autoimmune diseases, cancer and any genetic disorder that effects liver function such as Wilson’s disease; No history of lipid-lowering drug use; No pregnancy and breast-feeding; No use of vitamin E supplements; No use of drugs that caused fatty liver, like tetracycline, vitamin A, methotrexate, amiodarone, tamoxifen, etc.; No history of use of hepatotoxic drugs in the last 6 months; No long-term use of herbal drugs Exclusion criteria: If the patient indicates hypersensitivity reactions to cinnamon, becomes pregnant or not interested, and also if the level of liver enzymes rises at the end of the forth week due to cinnamon consumption, the patient will be excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in ALT serum level. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits.;Reduction in AST serum level. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile improvement. Timepoint: Before intervention, at the end of the fourth week of intervention, at the end of the eighth week of intervention. Method of measurement: Blood test and laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Moeeni
Gastroenterohepatology Research Center of Shiraz
Outcome results
None listed